IPO - Profile


Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$22.00 13,850,000 Positive High 43.4%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • PricewaterhouseCoopers LLP

Deal Highlights

We are an artificial intelligence-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Our goal is to change the pharmaceutical industry’s underlying pharmacoeconomic model, what we call “Shifting the Curve”, by improving the probability of success, time and cost involved with creating new medicines. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates. We have built a complete end-to-end solution of artificial intelligence, or AI, and experimental technologies for target identification, drug candidate design, translational models and patient selection. Our platform has enabled us to design candidate drug molecules that have progressed into clinical trials as well as to prospectively provide patients with potentially more applicable drug therapies through AI guided assessment. Our patient-first AI process is comprised of the following four elements: • Precision Target: deep learning approaches to prioritise projects; ? • Precision Design: an extensive platform of AI technologies to design innovative drugs; ? • Precision Experiment: tech-enabled precision experimentation to derive better data; and ? • Precision Medicine: integrated analysis of patient data to ensure clinical relevance. ? Our AI-design capabilities include a wide range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyse patient tissues to prioritise the molecules that are likely to provide the best response for an individual’s specific tumour.

Deal Tracker

IPO Dates

Filing 27 Sep, 2021

Offer 01 Oct, 2021

Look Ahead

Lock Up Expiry Apr 01, 2022

IPO Terms

Offer Price $22.00
Offer Size 13M

Market Sentiments

Stock Price